异基因造血干细胞移植患者中更昔洛韦/缬更昔洛韦的临床药代动力学、药效学与毒效学系统综述
该系统综述检索了PUBMED和EMBASE数据库1946年至2019年的研究,纳入14项研究共179例异基因造血干细胞移植患者,评估更昔洛韦/缬更昔洛韦的药代动力学、药效学与毒效学。药代参数个体间变异大且不同于其他人群,仅一项研究发现中性粒细胞减少与更昔洛韦峰浓度和谷浓度升高相关,未发现治疗药物监测与临床结局的关联。
要点
- 更昔洛韦/缬更昔洛韦在alloHCT患者中的药代参数个体间变异大,且不同于实体器官移植和HIV感染人群。
- 仅一项研究显示中性粒细胞减少与更昔洛韦峰浓度和谷浓度升高相关,其他药效学/毒效学关系未明确。
- 部分机构开展更昔洛韦治疗药物监测,但未发现其与临床结局的关联,需进一步研究确定治疗范围。
核心结论
- 需要进一步研究更昔洛韦/缬更昔洛韦在alloHCT患者中的药代动力学、药效学与毒效学,以确定更可靠的治疗范围并量化治疗药物监测的潜在价值。
研究设计与样本
- 系统综述,检索PUBMED和EMBASE数据库1946年至2019年的文献,纳入14项研究共179例异基因造血干细胞移植患者,仅限年龄>12岁且英文发表的研究。
主要发现
- 药代动力学参数显示显著的个体间变异,且不同于实体器官移植和HIV感染患者。
- 仅一项研究发现中性粒细胞减少与更昔洛韦峰浓度和谷浓度升高相关,未发现其他显著的药效学和毒效学关系。
- 部分机构开展更昔洛韦治疗药物监测,但未发现其与临床结局的关联。
关键数值与推荐
- 共纳入14项研究179例患者,其中6项仅考察更昔洛韦药代动力学,8项同时考察药效学和毒效学。
临床怎么用
- 临床可关注更昔洛韦/缬更昔洛韦在alloHCT患者中的个体间变异,但当前证据尚不足以支持常规治疗药物监测以改善结局。
局限性
- 纳入研究数量有限(14项)且样本量小(179例),仅一项研究报道了毒效学关联,未发现治疗药物监测与临床结局的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ganciclovir (GCV) and valganciclovir (VGCV) are the first-line agents used to prevent and treat cytomegalovirus (CMV) infection in allogeneic haematopoietic stem cell transplant (alloHCT) patients. OBJECTIVE: The aim of this work was to describe available data for the clinical pharmacokinetics, pharmacodynamics and toxicodynamics of GCV and VGCV and the potential of a therapeutic drug monitoring strategy to improve outcomes in the alloHCT population. METHODS: We systematically reviewed the pharmacokinetics (dose-exposure), pharmacodynamics (exposure-efficacy) and toxicodynamics (exposure-toxicity) of GCV and VGCV in alloHCT patients with CMV infection. Studies including alloHCT patients treated for CMV infection reporting the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV or VGCV were searched for using the PUBMED and EMBASE databases from 1946 to 2019. Only studies involving participants > 12 years of age and available in the English language were included. RESULTS: A total of 179 patients were included in the 14 studies that met the inclusion criteria, of which 6 examined GCV pharmacokinetics only, while 8 also examined GCV pharmacodynamics and toxicodynamics. Reported pharmacokinetic parameters showed considerable interpatient variability and were different from other populations, such as solid organ transplant and human immunodeficiency virus-infected patients. Only one study found a correlation between neutropenia and elevated peak and trough GCV concentrations, with no other significant pharmacodynamic and toxicodynamic relationships identified. While therapeutic drug monitoring of GCV is performed in some institutions, no association between GCV therapeutic drug monitoring and clinical outcomes was identified. CONCLUSION: Further studies of the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV/VGCV in alloHCT patients are required to identify a more robust therapeutic range and to subsequently quantify the potential value of therapeutic drug monitoring of GCV/VGCV in the alloHCT population.
引用
- Selby PR, Shakib S, Peake SL, et al. A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients. Clin Pharmacokinet. 2021. PMID: 33515202. doi:10.1007/s40262-020-00982-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。